Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

In a surprising twist that bridged partisan divides and reignited debate around the pharmaceutical supply chain, billionaire ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

At best, such products are misleading, said Jamie Alan, an associate professor of pharmacology and toxicology at Michigan State University’s College of Human Medicine. So-called GLP-1 ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

As previously announced, Lexaria has already demonstrated in human testing, enhanced delivery performance to the world's ONLY existing orally dosed GLP-1 drug: Rybelsus® (semaglutide), owned by ...

Use of GLP-1 receptor agonists was associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor ...